Human parainfluenza virus (HPIV)

Human parainfluenza viruses (HPIVs) are a group of four distinct serotypes (HPIV-1 through 4) belonging to the Paramyxoviridae family. They are enveloped, negative-sense, single-stranded RNA viruses that primarily cause upper and lower respiratory tract illnesses, particularly in children, the elderly, and immunocompromised individuals. HPIVs are a leading cause of croup (laryngotracheobronchitis) and contribute significantly to pediatric hospitalizations for bronchiolitis and pneumonia worldwide (StatPearls, 2023; NIH, 2022). At the molecular level, the virus utilizes two surface glycoproteins—the Hemagglutinin-neuraminidase (HN) protein for attachment and the Fusion (F) protein for entry—which are the primary targets for vaccine and drug development. While there are currently no FDA-approved vaccines or specific antiviral therapies for HPIV, management typically involves supportive care. Investigational therapies like DAS181 (a sialidase) and various fusion inhibitors aim to disrupt the viral life cycle by preventing host cell binding or entry (PubMed, 2021). Because HPIV is a pathogen rather than a single molecule, it is classified as a biological target rather than a specific therapeutic receptor or enzyme.

Other names

HPIVsHuman respirovirusHuman orthorubulavirusParainfluenza virus

Current therapeutic approaches involve broad-spectrum antiviral activity, such as inhibiting viral RNA synthesis (Ribavirin) or enzymatic cleavage of sialic acid receptors on host cells to prevent viral entry (DAS181). Investigational monoclonal antibodies and small molecules target specific viral proteins like the Hemagglutinin-neuraminidase (HN) and Fusion (F) proteins to block attachment and membrane fusion.